MenACWY-CRM

BIOLOGICAL16 trials

Sponsors

Novartis Vaccines, GlaxoSmithKline, Pfizer, Canadian Immunization Research Network

Conditions

Hepatitis AHepatitis BInfections, MeningococcalMeningococcal DiseaseMeningococcal Disease, InvasiveMeningococcal InfectionsMeningococcal MeningitisMeningococcal Vaccine

Phase 2

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

CompletedNCT00310856

Novartis VaccinesMeningococcal Meningitis

Start: 2005-06-30End: 2006-11-30Updated: 2018-10-09

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

CompletedNCT00488683

Novartis VaccinesMeningococcal Disease

Start: 2007-07-31End: 2009-06-30Updated: 2014-10-01

Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

CompletedNCT01994629

Novartis VaccinesMeningococcal Disease

Start: 2013-11-30End: 2014-10-31Updated: 2015-11-04

Phase 3

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

CompletedNCT00616421

Novartis VaccinesMeningococcal Infections

Start: 2008-03-31End: 2009-10-31Updated: 2016-02-15

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

CompletedNCT00626327

Novartis VaccinesMeningococcal Infections

Start: 2008-02-29End: 2010-10-31Updated: 2013-04-19

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

CompletedNCT01000311

Novartis VaccinesMeningococcal Disease

Start: 2009-11-30End: 2011-11-30Updated: 2014-04-21

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

CompletedNCT01214837

Novartis VaccinesMeningococcal Disease, Meningococcal Meningitis

Start: 2010-10-31End: 2012-05-31Updated: 2018-10-09

Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine

CompletedNCT01345721

Novartis VaccinesMeningococcal Disease

Start: 2011-05-31End: 2011-09-30Updated: 2018-06-18

Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

CompletedNCT01453348

Novartis VaccinesHepatitis A, Hepatitis B, Meningococcal Disease +1

Start: 2011-10-31End: 2012-01-31Updated: 2017-06-08

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

CompletedNCT01682876

GlaxoSmithKlineInfections, Meningococcal, Meningococcal Disease

Start: 2012-10-07End: 2014-05-30Updated: 2019-06-14

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia

CompletedNCT01725217

Novartis VaccinesMeningococcal Disease

Start: 2012-11-30End: 2013-03-31Updated: 2023-04-28

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

CompletedNCT03135834

PfizerMeningococcal Vaccine

Start: 2017-04-24End: 2022-10-25Updated: 2023-08-08

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

CompletedNCT04440163

PfizerMeningococcal Vaccine

Start: 2020-06-17End: 2022-07-24Updated: 2023-04-18

Phase 4

Adolescent MenACWY Booster Study

CompletedNCT03694405

Canadian Immunization Research NetworkMeningococcal Disease, Invasive

Start: 2018-09-20End: 2021-08-01Updated: 2022-03-11

Unknown Phase

Safety of MenACWY-CRM Vaccination in Adolescents

CompletedNCT01452464

Novartis VaccinesMeningococcal Disease

Start: 2011-09-30End: 2015-02-28Updated: 2015-02-26

Safety Surveillance of MenACWY-CRM Vaccine in Children

CompletedNCT01452438

Novartis VaccinesMeningococcal Disease

Start: 2011-09-30End: 2015-07-31Updated: 2015-08-06

Related Papers

Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose

Vaccine2024-11-083 citations

1638. Development of a Model to Estimate Persistence of hSBA Titers Over Time Following a Primary Series and Booster Dose of the Pentavalent Meningococcal MenABCWY Vaccine

Open Forum Infectious Diseases2023-11-27

Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.

2023-08-1112 citations

Bactericidal antibodies against hypervirulent <i>Neisseria meningitidis</i> C field strains following MenC-CRM or MenACWY-CRM priming and MenACWY-CRM booster in children

Human Vaccines & Immunotherapeutics2020-12-161 citations

6. Pentavalent Meningococcal (MenABCWY) Vaccine is Safe and Well Tolerated With Immunogenicity Noninferior to Coadministered MenB-FHbp and MenACWY-CRM in a Phase 2 Study of Healthy Adolescents and Young Adults

Open Forum Infectious Diseases2020-10-014 citations

Safety of Quadrivalent Meningococcal Conjugate Vaccine in Children 2-10 Years.

2017-11-018 citations

Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants

The Pediatric Infectious Disease Journal2015-10-1713 citations

Immunogenicity and Safety of Concomitant Administration of a Combined Hepatitis A/B Vaccine and a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults

Journal of Travel Medicine2014-12-0913 citations

Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.

2010-10-2940 citations